De-risking Drug Development
Metabolism-based causes of drug attrition must be tackled through intelligent and early risk mitigation strategies.
Guy Webber |
Risk management has become an important discipline for firms developing new prescription drugs. It is said that only one of the 10,000 molecules entering drug discovery will ultimately reach the market – and, even then, it is not certain that expensive development costs will be recouped.
There can be few industries where the risk of failure is higher than in the drug development sector. Is it possible to shorten the odds a little? I believe so, but we need to understand the causes of drug attrition and deploy appropriate resources to gauge the level of associated risk. In short, we need to get better at identifying molecules that have a better chance of surviving the development process.
Enjoy our FREE content!
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Login if you already created an account
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
